vs
ICU MEDICAL INC（ICUI）与Worthington Steel, Inc.（WS）财务数据对比。点击上方公司名可切换其他公司
Worthington Steel, Inc.的季度营收约是ICU MEDICAL INC的1.6倍（$871.9M vs $540.7M），Worthington Steel, Inc.净利率更高（2.2% vs -2.9%，领先5.1%），Worthington Steel, Inc.同比增速更快（18.0% vs -14.1%），Worthington Steel, Inc.自由现金流更多（$74.6M vs $36.0M），过去两年Worthington Steel, Inc.的营收复合增速更高（3.9% vs -2.3%）
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
沃辛顿钢铁是总部位于美国俄亥俄州哥伦布市的工业制造企业，下设消费品和建筑建材两大业务板块，主营各类压力容器的设计与生产，覆盖丙烷、氧气、氦气储罐，制冷剂及工业气瓶，露营与民用气瓶，以及用于存储、处理、加热、扩容和流量控制的供水系统罐体等产品。
ICUI vs WS — 直观对比
营收规模更大
WS
是对方的1.6倍
$540.7M
营收增速更快
WS
高出32.1%
-14.1%
净利率更高
WS
高出5.1%
-2.9%
自由现金流更多
WS
多$38.6M
$36.0M
两年增速更快
WS
近两年复合增速
-2.3%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $540.7M | $871.9M |
| 净利润 | $-15.7M | $18.8M |
| 毛利率 | 37.5% | 10.7% |
| 营业利润率 | 1.0% | 2.5% |
| 净利率 | -2.9% | 2.2% |
| 营收同比 | -14.1% | 18.0% |
| 净利润同比 | 34.0% | 46.9% |
| 每股收益（稀释后） | $-0.63 | $0.37 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICUIWS
| Q4 25 | $540.7M | $871.9M | ||
| Q3 25 | $537.0M | $872.9M | ||
| Q2 25 | $548.9M | $832.9M | ||
| Q1 25 | $604.7M | $687.4M | ||
| Q4 24 | $629.8M | $739.0M | ||
| Q3 24 | $589.1M | $834.0M | ||
| Q2 24 | $596.5M | — | ||
| Q1 24 | $566.7M | $805.8M |
净利润ICUIWS
| Q4 25 | $-15.7M | $18.8M | ||
| Q3 25 | $-3.4M | $36.8M | ||
| Q2 25 | $35.3M | $55.7M | ||
| Q1 25 | $-15.5M | $13.8M | ||
| Q4 24 | $-23.8M | $12.8M | ||
| Q3 24 | $-33.0M | $28.4M | ||
| Q2 24 | $-21.4M | — | ||
| Q1 24 | $-39.5M | $49.0M |
毛利率ICUIWS
| Q4 25 | 37.5% | 10.7% | ||
| Q3 25 | 37.4% | 13.2% | ||
| Q2 25 | 37.9% | 15.2% | ||
| Q1 25 | 34.7% | 11.8% | ||
| Q4 24 | 36.1% | 10.8% | ||
| Q3 24 | 34.8% | 12.0% | ||
| Q2 24 | 34.8% | — | ||
| Q1 24 | 32.7% | 14.9% |
营业利润率ICUIWS
| Q4 25 | 1.0% | 2.5% | ||
| Q3 25 | 2.6% | 5.5% | ||
| Q2 25 | 1.9% | 8.0% | ||
| Q1 25 | 2.1% | 2.7% | ||
| Q4 24 | 6.0% | 2.6% | ||
| Q3 24 | 1.4% | 5.2% | ||
| Q2 24 | 1.3% | — | ||
| Q1 24 | -1.9% | 8.2% |
净利率ICUIWS
| Q4 25 | -2.9% | 2.2% | ||
| Q3 25 | -0.6% | 4.2% | ||
| Q2 25 | 6.4% | 6.7% | ||
| Q1 25 | -2.6% | 2.0% | ||
| Q4 24 | -3.8% | 1.7% | ||
| Q3 24 | -5.6% | 3.4% | ||
| Q2 24 | -3.6% | — | ||
| Q1 24 | -7.0% | 6.1% |
每股收益（稀释后）ICUIWS
| Q4 25 | $-0.63 | $0.37 | ||
| Q3 25 | $-0.14 | $0.72 | ||
| Q2 25 | $1.43 | $1.11 | ||
| Q1 25 | $-0.63 | $0.27 | ||
| Q4 24 | $-0.97 | $0.25 | ||
| Q3 24 | $-1.35 | $0.56 | ||
| Q2 24 | $-0.88 | — | ||
| Q1 24 | $-1.63 | $0.98 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $89.8M |
| 总债务越低越好 | — | $72.1M |
| 股东权益账面价值 | $2.1B | $1.1B |
| 总资产 | $4.1B | $2.1B |
| 负债/权益比越低杠杆越低 | — | 0.06× |
8季度趋势，按日历期对齐
现金及短期投资ICUIWS
| Q4 25 | — | $89.8M | ||
| Q3 25 | — | $78.3M | ||
| Q2 25 | — | $38.0M | ||
| Q1 25 | — | $63.3M | ||
| Q4 24 | $308.6M | $52.0M | ||
| Q3 24 | $312.5M | $36.0M | ||
| Q2 24 | $302.6M | — | ||
| Q1 24 | $251.4M | $60.8M |
总债务ICUIWS
| Q4 25 | — | $72.1M | ||
| Q3 25 | — | $73.4M | ||
| Q2 25 | — | $151.5M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $115.0M | ||
| Q3 24 | — | $122.2M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $147.2M |
股东权益ICUIWS
| Q4 25 | $2.1B | $1.1B | ||
| Q3 25 | $2.1B | $1.1B | ||
| Q2 25 | $2.1B | $1.1B | ||
| Q1 25 | $2.0B | $1.0B | ||
| Q4 24 | $2.0B | $1.0B | ||
| Q3 24 | $2.0B | $1.0B | ||
| Q2 24 | $2.0B | — | ||
| Q1 24 | $2.1B | $937.6M |
总资产ICUIWS
| Q4 25 | $4.1B | $2.1B | ||
| Q3 25 | $4.1B | $2.2B | ||
| Q2 25 | $4.1B | $2.0B | ||
| Q1 25 | $4.2B | $1.8B | ||
| Q4 24 | $4.2B | $1.7B | ||
| Q3 24 | $4.3B | $1.8B | ||
| Q2 24 | $4.3B | — | ||
| Q1 24 | $4.3B | $1.8B |
负债/权益比ICUIWS
| Q4 25 | — | 0.06× | ||
| Q3 25 | — | 0.07× | ||
| Q2 25 | — | 0.14× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.11× | ||
| Q3 24 | — | 0.12× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.16× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.6M | $99.3M |
| 自由现金流经营现金流 - 资本支出 | $36.0M | $74.6M |
| 自由现金流率自由现金流/营收 | 6.6% | 8.6% |
| 资本支出强度资本支出/营收 | 4.6% | 2.8% |
| 现金转化率经营现金流/净利润 | — | 5.28× |
| 过去12个月自由现金流最近4个季度 | $91.8M | $72.5M |
8季度趋势，按日历期对齐
经营现金流ICUIWS
| Q4 25 | $60.6M | $99.3M | ||
| Q3 25 | $56.7M | $-6.3M | ||
| Q2 25 | $11.2M | $53.9M | ||
| Q1 25 | $51.3M | $53.8M | ||
| Q4 24 | $40.2M | $68.0M | ||
| Q3 24 | $36.1M | $54.6M | ||
| Q2 24 | $82.0M | — | ||
| Q1 24 | $45.8M | $44.7M |
自由现金流ICUIWS
| Q4 25 | $36.0M | $74.6M | ||
| Q3 25 | $27.6M | $-35.7M | ||
| Q2 25 | $-8.5M | $8.4M | ||
| Q1 25 | $36.7M | $25.2M | ||
| Q4 24 | $16.1M | $33.2M | ||
| Q3 24 | $16.2M | $33.1M | ||
| Q2 24 | $62.5M | — | ||
| Q1 24 | $29.9M | $22.3M |
自由现金流率ICUIWS
| Q4 25 | 6.6% | 8.6% | ||
| Q3 25 | 5.1% | -4.1% | ||
| Q2 25 | -1.5% | 1.0% | ||
| Q1 25 | 6.1% | 3.7% | ||
| Q4 24 | 2.6% | 4.5% | ||
| Q3 24 | 2.7% | 4.0% | ||
| Q2 24 | 10.5% | — | ||
| Q1 24 | 5.3% | 2.8% |
资本支出强度ICUIWS
| Q4 25 | 4.6% | 2.8% | ||
| Q3 25 | 5.4% | 3.4% | ||
| Q2 25 | 3.6% | 5.5% | ||
| Q1 25 | 2.4% | 4.2% | ||
| Q4 24 | 3.8% | 4.7% | ||
| Q3 24 | 3.4% | 2.6% | ||
| Q2 24 | 3.3% | — | ||
| Q1 24 | 2.8% | 2.8% |
现金转化率ICUIWS
| Q4 25 | — | 5.28× | ||
| Q3 25 | — | -0.17× | ||
| Q2 25 | 0.32× | 0.97× | ||
| Q1 25 | — | 3.90× | ||
| Q4 24 | — | 5.31× | ||
| Q3 24 | — | 1.92× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.91× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
WS
| Direct | $844.1M | 97% |
| Toll | $27.8M | 3% |
